Xponance Inc. Has $20.74 Million Position in Zoetis Inc. (NYSE:ZTS)

Xponance Inc. lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,096 shares of the company’s stock after selling 538 shares during the quarter. Xponance Inc.’s holdings in Zoetis were worth $20,743,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP increased its position in shares of Zoetis by 2.5% during the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock worth $2,147,730,000 after purchasing an additional 297,044 shares during the last quarter. Morgan Stanley increased its position in shares of Zoetis by 34.6% during the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock worth $1,593,395,000 after purchasing an additional 2,796,694 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Zoetis by 0.3% during the 1st quarter. Geode Capital Management LLC now owns 9,739,370 shares of the company’s stock worth $1,617,464,000 after purchasing an additional 27,097 shares during the last quarter. Northern Trust Corp increased its position in shares of Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock worth $1,068,804,000 after purchasing an additional 196,771 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Zoetis during the 4th quarter worth approximately $745,861,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on ZTS shares. Barclays boosted their price target on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research report on Tuesday. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Stifel Nicolaus reduced their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Finally, The Goldman Sachs Group lifted their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $221.75.

Zoetis Stock Performance

ZTS traded up $1.60 during trading on Thursday, hitting $153.11. The stock had a trading volume of 4,729,915 shares, compared to its average volume of 2,988,847. The company has a 50 day moving average price of $177.35 and a 200-day moving average price of $180.39. The firm has a market cap of $70.03 billion, a price-to-earnings ratio of 30.15, a P/E/G ratio of 2.34 and a beta of 0.85. Zoetis Inc. has a one year low of $148.48 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.15 earnings per share. As a group, research analysts predict that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.13%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.12% of the stock is currently owned by corporate insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.